Cocrystal Pharma (COCP) Liabilities from Discontinued Operations (2012 - 2013)
Cocrystal Pharma (COCP) posted Liabilities from Discontinued Operations of 1205702.0 for Q4 2013, down 58.35% sequentially from 2894579.0 in Q4 2012, and down 58.35% YoY from 2894579.0 in Q4 2012.
Cocrystal Pharma (COCP) Liabilities from Discontinued Operations (2012 - 2013) Analysis & Trends
Cocrystal Pharma has reported Liabilities from Discontinued Operations for 2 years, with the latest figure at 1205702.0 in Q4 2013.
- Quarterly Liabilities from Discontinued Operations fell 58.35% year-over-year to 1205702.0 in Q4 2013, while the trailing twelve-month figure through Dec 2013 was 1205702.0 (down 58.35% YoY) and the FY2013 annual result came in at 1205702.0, down 58.35% from the prior year.
- Liabilities from Discontinued Operations eased to 1205702.0 in Q4 2013 per COCP's latest filing, from 2894579.0 in the prior quarter.
- Over five years, Liabilities from Discontinued Operations peaked at 2894579.0 in Q4 2012 and troughed at 1205702.0 in Q4 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Cocrystal Pharma | 15.65 Mn | 13.33 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2013 | 1.21 Mn |
| Dec 31, 2013 | 1.21 Mn |
| Dec 31, 2012 | 2.89 Mn |
| Dec 31, 2012 | 2.89 Mn |